Dasatinib is a Yes, Bcr-ABL, Src, and Kit inhibitor, and has been approved by the Food and Drug Administration for the treatment of chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CP-CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) [20–22]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.